To study the differences in the effects of various drugs in patients suffering from metabolic syndrome, which is a cluster of conditions such as obesity, increased blood pressure and disordered cholesterol levels that increases the risk of heart diseases, diabetes and stroke.

Comparative efficacy of metformin, pioglitazone and rosuvastatin on metabolic profile in patients with metabolic syndrome.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/10/005139

Enrollment

140

Registered

2014-10-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Metabolic Syndrome

Interventions

Intervention1: Metformin: 500mg BD for 12weeks Intervention2: Pioglitazone: 15mg OD for 12weeks Intervention3: Rosuvastatin: 10mg OD for 12 weeks Control Intervention1: Diet and lifestyle modification

Eligibility

Inclusion criteria

Inclusion criteria: Patients with 18-60 years of age and either sex diagnosed with Metabolic Syndrome. Conformation to written informed consent.

Exclusion criteria

Exclusion criteria: Patient not willing to give informed consent, type I diabetes mellitus, type II diabetes mellitus(fasting plasma glucose of >126mg/dl), severely deranged lipid profile(TG >500 mg/dl, LDLC >250mg /dl), liver enzymes >2 times of upper limit and serum creatinine >2mg/dl, history of heart disease, familial dyslipidemia, hyper or hypothyroidism, major medical/surgical illness, hypersensitivity to any of the used drugs, pregnant and lactating females, patient on any other long term concomitant drugs known to affect glucose tolerance or lipid profile

Design outcomes

Primary

Measure	Time frame
Serum triglycerideTimepoint: Baseline and 12 weeks	—

Secondary

Measure	Time frame
Fasting plasma glucoseTimepoint: Baseline and 12 weeks;hsCRPTimepoint: Baseline and 12 weeks;Serum adiponectinTimepoint: Baseline and 12 weeks;Serum high density lipoproteinTimepoint: Baseline and 12 weeks;Waist circumferenceTimepoint: Baseline and 12 weeks	—

Countries

India

Contacts

Public ContactDr Sanjay Khattri

King Georges Medical University

dr.arpitjain@hotmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026